ArticleHaematologica2026
Locally manufactured
Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Would you, could you drive CARs to point-of-care manufacturing? Yes, you should!Haematologica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
Abstract
Locally manufactured chimeric antigen receptor T-cell (CAR T) therapy enables rapid manufacturing and a substantially shorter vein-to-vein time. However, its clinical efficacy compared to commercial CAR T products remains unclear. This retrospective study compared outcomes in patients with large B-cell lymphoma (LBCL) treated with a CD19-directed autologous locally manufactured CAR T product (CD28-based co-stimulation) versus axicabtagene-ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) across three academic centers. All patients had received at least two prior lines of therapy. Propensity score analysis for CAR T product adjusted for age, Karnofsky performance status, lactate dehydrogenase (LDH) level, primary refractory disease, and transformed histology was performed to account for underlying differences in treatment groups. Among 330 patients (132 axi-cel, 104 tisa-cel, 94 locally manufactured products), those treated with locally manufactured CAR T were younger, had higher performance status, and were more likely to present with elevated LDH and primary refractory disease. The median time from apheresis to CAR T infusion was significantly shorter with locally manufactured CAR T (11 days) than with axi-cel (38 days) or tisa-cel (44 days) (P<0.001). In adjusted analysis, a trend to improved progression-free survival with axi-cel was found when comparing locally manufactured products versus axi-cel (weighted hazard ratio [WHR]=1.54; 95% confidence interval [95% CI]: 1.00-2.37; P=0.051) and no difference between those given a locally manufactured product versus tisa-cel (WHR=0.71; 95% CI: 0.45-1.11; P=0.13). Overall survival was comparable across treatment groups: locally manufactured product versus axi-cel (WHR=1.35, 95% CI: 0.87-2.10; P=0.18) and locally manufactured product versus tisa-cel (WHR=0.85, 95% CI: 0.53-1.34; P=0.48). Rates of grade ≥2 cytokine release syndrome were lower with locally manufactured CAR T. These findings support locally manufactured CAR T as a clinically comparable alternative to commercial products for LBCL, with the potential advantage of rapid availability for patients with aggressive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.